Flow-injection analysis for meloxicam based on tris(2,2'-bipyridine) ruthenium(II)-Ce(IV) chemiluminescent system.
It was found that meloxicam could enhance the chemiluminescence (CL) of the tris(2,2'-bipyridine) ruthenium(II)-Ce(IV) system in the medium of sulfate acid. Based on this phenomenon a new flow-injection system with chemiluminescent detection has been proposed for determination of meloxicam. Under optimum conditions, meloxicam had a good linear relationship with the CL intensity in the concentration range of 6.0 10(-4) to 1.0 microg/mL and the detection limit was 3.7 x 10(-4 )microg/mL. The proposed method was applied to detect meloxicam in tablets and a satisfactory recovery was obtained. The possible mechanism for this CL system is also discussed in this paper.
Polarographic behaviour of meloxicam and its determination in tablet preparations and spiked plasma.
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID), which has a higher activity cyclooxygenase-2 (COX-2) than against cyclooxygenase-1 (COX-1), with potentially high anti-inflammatory and analgesic action. The voltammetric behaviour of meloxicam was studied using direct current (DC), differential pulse polarography (DPP) and cyclic voltammetry (CV). The influence of several variables (including nature of the buffer, pH, concentration, modulation amplitude, scan rate, drop size, etc.) was examined in DPP method for meloxicam. The best DPP response was obtained in acetate buffer pH 4.88. The peak currents were measured with a static mercury drop electrode at -1.49 V versus Ag/AgCl. Calibration curve for meloxicam was linear at a concentration range from 0.38 to 15.0 microg ml(-1). The method was validated and applied to the determination of meloxicam in tablets, which were in two different dosage forms. A spectrophotometric method reported in the literature was utilized as a comparison method. There were no significant differences between the results obtained by two methods. DPP method is also available and applicable for the determination of mentioned substance in plasma. Mean recovery was 99.20+/-0.37%. It was concluded that the developed method was accurate, sensitive, precise, reproducible and useful for the quality control of meloxicam in pharmaceuticals and spiked plasma.
Fatigue effects on the coordinative pattern during cycling: kinetics and kinematics evaluation.
The aim of the present study was to analyze the net joint moment distribution, joint forces and kinematics during cycling to exhaustion. Right pedal forces and lower limb kinematics of ten cyclists were measured throughout a fatigue cycling test at 100% of PO(MAX). The absolute net joint moments, resultant force and kinematics were calculated for the hip, knee and ankle joint through inverse dynamics. The contribution of each joint to the total net joint moments was computed. Decreased pedaling cadence was observed followed by a decreased ankle moment contribution to the total joint moments in the end of the test. The total absolute joint moment, and the hip and knee moments has also increased with fatigue. Resultant force was increased, while kinematics has changed in the end of the test for hip, knee and ankle joints. Reduced ankle contribution to the total absolute joint moment combined with higher ankle force and changes in kinematics has indicated a different mechanical function for this joint. Kinetics and kinematics changes observed at hip and knee joint was expected due to their function as power sources. Kinematics changes would be explained as an attempt to overcome decreased contractile properties of muscles during fatigue.